Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIN201104 in Healthy Volunteers and Asthma
NCT03058458Phase 1Completed
- Sponsor
- Revolo Biotherapeutics
- Start
- Jan 2017
- Primary completion
- Jan 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IRL201104 in asthma (4 arms), sponsored by Revolo Biotherapeutics. Primary endpoint: Treatment Emergent Adverse Events at 21 days. Started Jan 2017; status: completed.
02
Drugs
IRL201104
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03058458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03058458.